Tigenix Nv operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tigenix Nv with three other
companies in this sector in Belgium:
Thrombogenics Nv
(2016
sales of 7.10 million Euro [US$8.67 million]
of which 100%
was Royalty Income),
MDxHealth S.A.
(27.15 million Euro [US$33.15 million]
of which 100%
was Diagnostic Tools), and
argenx NV
(14.71 million Euro [US$17.96 million]
of which 62%
was License Fees).
Sales Analysis.
Sales increased substantially in 2016:
Tigenix Nv reported sales of 25.40 million Euro (US$31.01 million)
for the
year ending
December of 2016.
This
represents
an
increase of 4,629.1%
versus 2015, when the company's sales were 537,000.00 Euro.